Crossmark

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry

Crossref DOI link: https://doi.org/10.1038/s41588-018-0191-z

Published Online: 2018-08-20

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Durbin, Adam D. https://orcid.org/0000-0002-5472-9847
Zimmerman, Mark W. https://orcid.org/0000-0003-2489-3889
Dharia, Neekesh V. https://orcid.org/0000-0001-5048-067X
Abraham, Brian J. https://orcid.org/0000-0001-8085-3027
Iniguez, Amanda Balboni

Weichert-Leahey, Nina

He, Shuning

Krill-Burger, John M.

Root, David E.

Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
Tsherniak, Aviad https://orcid.org/0000-0002-3797-1877
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
Young, Richard A. https://orcid.org/0000-0001-8855-8647
Look, A. Thomas

Stegmaier, Kimberly https://orcid.org/0000-0003-0218-7895
License Information

Text and Data Mining valid from 2018-08-20
More Information

Article History

Received: 2 June 2017

Accepted: 25 May 2018

First Online: 20 August 2018

Competing interests

: R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, which is discovering and developing therapeutics directed at transcriptional pathways in cancer. K.S. and W.C.H. consulted for Novartis Pharmaceuticals as part of the Dana–Farber Cancer Institute/Novartis Drug Discovery Program. B.J.A. is a shareholder of Syros Pharmaceuticals. No other potential conflicts of interest are declared.